In the May 2009 problem of The Journal of Molecular Diagnostics , three articles describe improvements in cystic fibrosis genetic screening. In one content, Pratt et al describes a project coordinated by the Centers for Disease Control and Prevention’s Genetic Tests Reference Materials Program to develop a couple of reference components for the expanded cystic fibrosis panel of mutations. The public option of these materials will ensure the accuracy of cystic fibrosis genetic screening. The reports by Schwartz et al and Hantash et al recognize mutations that can lead to false screening results, either due to a big deletion in CFTR or due to mutations that hinder laboratory screening strategies.Grade 5 adverse occasions of any trigger are shown in Table S5 in the Supplementary Appendix. With the exception of the fatal pneumonitis, explained above, that occurred after crossover to crizotinib, no deaths were reported that were considered by the investigators to become related to treatment. Patient-Reported Outcomes Baseline scores about the QLQ-C30, QLQ-LC13, and EQ-5D are summarized in Desk S6 in the Supplementary Appendix. There is a significantly greater general improvement from baseline in global quality of life among individuals who received crizotinib than among those who received chemotherapy .